Title: Safety and efficacy of rapamycin on healthspan metrics after one year: PEARL Trial

Results

Authors: Girish Harinath[1,2], Virginia Lee[1,2], Andy Nyquist[1], Mauricio Moel[1], Jesper Hagemeier[1],

Stefanie L. Morgan[1,2, *], Anar Isman[1], Sajad Zalzala[1]

Affiliations:

[1.] AgelessRx, Ann Arbor MI, USA

[2.] Division of Research and Applied Sciences, AgelessRx, Ann Arbor MI, USA

[3.] Data and Analytics Division, AgelessRx, Ann Arbor MI, USA

* Corresponding author

Corresponding author: Stefanie L Morgan, stefanie@agelessrx.com

Abstract: Rapamycin has been shown to have longevity-enhancing effects in murine models,

but clinical data on its gerotherapeutic effects in humans remains limited. We performed a 48-

week double-blinded, randomized, and placebo-controlled decentralized study (Participatory

Evaluation of Aging with Rapamycin for Longevity [PEARL]; NCT04488601; registration date

2020-07-28) to evaluate the safety and efficacy of rapamycin in mitigating clinical signs of aging

in a normative aging cohort. Participants received 5 or 10 mg / week of compounded

rapamycin, or placebo for 48 weeks. Safety, adverse events (AEs) and blood biomarkers were

collected. Efficacy was assessed using DEXA scan-based measures and standardized surveys

assessing quality of life (QoL) and frailty. We did not detect significant differences in safety

blood biomarkers, or moderate to severe AEs between the rapamycin treatment groups and

placebo after 48 weeks. We detected dose-dependent (10 mg group) and sex-specific

improvements in lean tissue mass, pain, social functioning, overall QoL, and overall

osteoarthritis score in females, and in bone mineral content in men. Additionally, some

individuals receiving rapamycin experienced significant improvements in body composition

metrics that were associated with beneficial changes in gut health and lipid metabolism. We

conclude that low-dose, intermittent rapamycin administration over the course of 48 weeks is

safe and induces sex-specific improvements in multiple aspects of healthspan, with the most

robust improvements in lean tissue mass in women taking 10 mg rapamycin/week. Future work

will aim to identify biometric signatures of clinical effectiveness to inform personalized

treatment strategies that more broadly maximize efficacy and minimize side effects.

Keywords: rapamycin, aging, healthspan, longevity

Introduction

Aging is the biggest risk factor for all major chronic diseases, accounting for nearly 70% of human mortality [1-3]. While advancements in medical technologies and public health practices over the past 150 years have led to longer lifespans less shaped by natural selection, the period of disease and disability-free life often referred to as "healthspan" has not kept pace [4]. In conjunction with an epidemic of poor lifestyle habits, this has collectively led to a growing chasm between lifespan and healthspan known as the healthspan gap, which in the United States lasts several decades and is characterized by a high burden of functional disability and age-related diseases (such as type 2 diabetes, osteoarthritis, and Alzheimer's) that often coexist as multi-morbidities [5]. While significant research has historically focused on treating these diseases individually, a growing body of work within translational geroscience explores developing gerotherapeutics that slow the aging process and delay the onset or prevent age-related disease altogether [6].

The field of translational geroscience has made rapid advancements in recent years, due in large part to strategic utilization of interventions already approved for other conditions by the US Food and Drug Administration (FDA) [7]. By repurposing such drugs for their potential to target the biology of aging and extend healthy longevity, clinical validation is fast-tracked to permit more immediate collection of application-specific efficacy data. Notable among these is rapamycin, which is widely used for its purported longevity and healthspan benefits within the pro-longevity community [8]. While evidence supports a role for rapamycin in improving life- and healthspans in preclinical studies [9], little data exists on its clinical efficacy in normative aging humans.

As an FDA-approved small molecule drug, rapamycin is an evolutionarily conserved inhibitor of the mammalian target of rapamycin serine/threonine kinase complex 1 (mTORc1), a known regulator of aging processes [10, 11]. Hyperactivity of mTORC1 has been linked to multiple chronic disease processes in nearly every organ system, while mTORC1 inhibition induced by caloric restriction and rapamycin or its derivatives (rapalogs) has been shown to reliably extend lifespan and healthspan across organisms from yeast to non-human primates [12-21]. Rapamycin-mediated mTORC1 inhibition has demonstrated particular efficacy as a

geroprotective intervention in mice, extending lifespan in heterogeneous genetic backgrounds

across multiple studies from independent labs at multiple dosages, dosing periods, and

regimens, even in elderly animals [14, 16, 18, 21, 22].

While rapamycin has demonstrated a more pronounced lifespan-enhancing effect in

female than male mice, mitigation or reversal of age-associated changes in multiple organ

tissues and the immune system have been observed for both sexes [23-25]. These findings have

been reproduced in companion dogs and marmosets, however, clinical data on rapamycin's

gerotherapeutic effects in humans remains limited [9, 12, 17, 26]. Given the substantial promise

in preclinical data, it is essential to obtain a deeper understanding and clearly define the clinical

benefits of rapamycin use for improving healthy aging in the generally healthy, adult

population. In particular, it will be important to understand how rapamycin may impact the

phenotypes of the biological aging process that substantially increases the risk of age-related

disease and mortality, such as an accumulation of visceral adipose tissue (VAT) and a loss of

lean muscle tissue and bone mass [27-32]. These are some of the most salient and functionally

consequential measures of biological aging, which frequently lead to reduced quality of life

(QoL), increased pain, and limited mobility, particularly for post-menopausal women [33, 34].

Collectively, this contributes to the marked decline in health that often occurs during this time

period [33]. It has been suggested that use of low-dose rapamycin may mitigate these features

of the aging process, enhancing healthspan [25, 35, 36].

Widespread adoption of rapamycin as a gerotherapeutic has historically been limited by

concerns regarding its known impact on immunosuppression, hyperlipidemia, and

hyperglycemia [37]. However, the vast majority of these effects stem from high, chronically

administered doses utilized in severely ill organ transplant or cancer patients, where the clinical

aim is inhibition of the immune system or anti-tumorigenic effects. In contrast, as a

gerotherapeutic for normative aging populations, low-dose, intermittent rapamycin is revealing

promise for minimizing side effects while still mitigating aspects of age-related decline [38-40].

For example, Mannick *et al.* demonstrated that healthy elderly individuals taking 0.5 mg of a

rapalog daily or 5 mg/ week for 6 weeks mitigated age-related immune decline by enhancing

the adaptive immune system's response to vaccination [41]. This supports our recent findings

from a study of 333 low-dose rapamycin users indicating a high perceived QoL and improved

health outcomes compared to non-users [8]. Preliminary data suggest that these effects stem

from a partial inhibition of mTORc1 in low-dose rapamycin (rather than the complete inhibition

observed at higher doses), which has been demonstrated to mitigate age-related decline by

stimulating autophagy, reducing senescent burden, and reducing pro-inflammatory cytokines

that drive chronic inflammation [9, 15, 24, 42, 43]. While promising findings such as these have

encouraged some physicians to prescribe off-label rapamycin as a therapy to maintain

healthspan, there are many open questions that require further study, particularly in a clinical

setting.

An important gap in the clinical understanding of rapamycin for longevity is that to date,

no long-term randomized controlled trials (RCT) have been conducted to explore low-dose,

intermittent rapamycin regimens for improving multiple healthspan metrics in normative aging

cohorts. The current study, the Participatory Evaluation of Aging with Rapamycin for Longevity

(PEARL) trial, aimed to address this gap. PEARL represents the largest and longest clinical study

of rapamycin use for healthy aging performed to date. This 48-week double-blinded,

randomized placebo-controlled decentralized study evaluated the safety and efficacy of

rapamycin in mitigating clinical signs of aging in a generally healthy cohort. Here, we present

the first evidence to date, to our knowledge, that low-dose rapamycin administration is safe

over the course of 48 weeks and induces sex-specific improvements in lean muscle mass, bone

mineral content, aspects of age-related frailty, and overall QoL. Further, we highlight additional

benefits observed specifically in rapamycin responders that may offer mechanistic insights into

key biological drivers of clinical effectiveness that will be investigated in greater depth in future

studies.

Methods

Study design

The PEARL study was a decentralized, single-center, prospective, double-blind, placebo-

controlled trial assessing rapamycin in healthy individuals aged 50-85 years, to determine the

safety and efficacy in mitigating aging-related decline (**Supplementary Figure S1**).

The study was conducted in accordance with the standards of Good Clinical Practice, as

defined by the International Conference on Harmonisation and all applicable federal and local

regulations. The study protocol was approved by the institutional review board of the Institute

of Regenerative and Cellular Medicine in May 2020 (IRCM; approval number IRCM-2020-252).

Study endpoints

The primary endpoints of this study included safety, which included the collection of

adverse events (AEs), safety blood biomarkers, and visceral adiposity. Secondary endpoints

included efficacy blood biomarkers, DEXA scan-determined lean tissue mass and bone mineral

content, and standardized surveys assessing quality of life and frailty.

Study population

Participants were recruited via the AgelessRx online medical platform. Patients were

screened for eligibility, and if deemed eligible, informed consent was obtained for participation

in the study.

Participants were eligible for the study if they were aged between 50 and 85 years at

the start of the study, were interested in taking rapamycin off-label, were willing to undergo

minimally invasive tests, and were in good health or had well-managed clinically-stable chronic

diseases. Participants were excluded from the study if they had anemia, neutropenia, or

thrombocytopenia, were premenopausal, were scheduled to undergo major surgery in next 12

months, were undergoing or were scheduled to undergo chemotherapy, were scheduled for

immunosuppressant therapy for an organ transplant, had impaired wound healing or history of

chronic open wound, untreated dyslipidemia, impaired hepatic function, chronic infections

requiring ongoing treatment or monitoring (e.g. human immunodeficiency virus/acquired

immunodeficiency syndrome, chronic Lyme disease), allergy to rapamycin, clinically-relevant

primary or secondary immune dysfunction or deficiency, chronic oral corticosteroid or

immunosuppressant medication use, fibromyalgia, chronic fatigue syndrome/myalgic

encephalitis, breast implant illness, congestive heart failure, impaired renal function, poorly

controlled diabetes, type I or insulin-dependent type II diabetes, untreated or treated within

the last five years for substance abuse disorder, and untreated or poorly controlled mental

health disorder. Further, those who had taken metformin, rapamycin, or rapalogs were

excluded unless the participant agreed to a 6 month washout period prior to the start of the

trial.

Treatments

Study participants were randomized into three groups: receiving 5 mg of rapamycin, 10

mg of rapamycin, or placebo, once per week. Placebo capsules were compounded to look

similar and were taken orally (Belmar Pharma Solutions (Golden, CO, USA)). Study participants

were prescribed the drug for 48 weeks upon enrollment in the study and were dispensed

supplies for 12 weeks at a time.

Assessments

All assessments were performed at baseline, after 24 weeks, and after 48 weeks of

rapamycin treatment. Blood testing was performed two additional times, at 2 weeks and 4

weeks of treatment, to evaluate safety. All blood testing was performed by local Quest

Diagnostics of LabCorp laboratories, and included complete blood count (CBC), comprehensive

metabolic panel, liver function tests, renal function tests, and lipid panels. DEXA body

composition scans were performed primarily by DexaFit or Fitnescity locations, based on local

availability, though some participants utilized third party locations based on site availability.

Regardless of site, the outcome measures obtained by DEXA scans were body mass index (BMI),

visceral fat, bone mineral content, bone mineral density, and lean tissue mass. Gut health was

evaluated using the Thorne Gut Health test.

Summary health scores were calculated as a sum of responses on baseline survey

responses of health for questions of frequency of use of smoking, consuming caffeinated

beverages, consuming alcoholic beverages, eating sugary, salty, or "junk" foods, exercise

(vigorous and moderate intensity), and weight. Benefit Score was calculated by ranking the

percent change on each DEXA measure evenly into high, medium, and low benefit, and

summing scores into a meta score. VAT measures were reverse-scored, as decrease in VAT raw

values corresponds with improvement on this measure. The summary meta score was then

again divided evenly into a high, medium, and low ranking. High scores were considered

"improved", and low scores were considered "decline", while in-between scores were

considered "stasis".

Health-related QoL was assessed by the short-form 36 (SF-36) survey, which consists of

36 questions covering eight health domains: physical functioning, role limitations due to

physical health, bodily pain, general health perceptions, vitality (energy levels), social

functioning, role limitations due to emotional problems, and emotional health [44]. The

responses are scored and summarized to provide a profile of an individual's perceived health

status. Pain, fitness, and functional limitations were assessed using the Western Ontario and

McMaster Universities Osteoarthritis (WOMAC) index, which is a questionnaire that is

commonly used to assess the health status of individuals with osteoarthritis of the hip and knee

[45]. It consists of 24 items divided into three subscales: pain, stiffness, and physical function.

The responses are scored to provide quantitative assessments of the severity of symptoms and

functional limitations associated with osteoarthritis.

Adverse Events

Adverse events (AEs) were obtained through weekly monitoring forms sent out to

participants. Clinical trial staff reviewed and documented AEs. Both expected (already known)

and unexpected AEs were reported and documented. A full list is presented in **Table 2**.

Statistical analyses

All initial analyses were performed by researchers blinded to the study treatment.

Demographic and baseline characteristics were summarized using descriptive statistics. All data

were tested for normality using visual inspection of histograms and Q-Q plots, and Shapiro-

Wilks tests were performed. Data were summarized using mean and standard deviation (SD)

and where appropriate, counts and percentages were reported. Baseline data were compared

between the three treatment arms using Analysis of Variance (ANOVA), independent t-test or

χ^2 test. To compare the difference in mean change from baseline to most recent follow-up (48

weeks) between treatment arms, we employed ANOVA and BMI-adjusted marginal mixed-

effect models. Following this, full age-, sex-, and BMI-adjusted linear mixed-effects models with

a repeated measures structure were conducted. Interaction terms (time by treatment arm, as

well as time by treatment arm by sex) were included to investigate group and gender effects

and their trajectory over time. Where appropriate, stratified post-hoc analyses were conducted

within sex and between treatment arms (10 mg vs. placebo and 5 mg vs. placebo). All analyses

were conducted using SPSS 28 (IBM, Armonk, NY, USA) and Python 3.10 (Python Software

Foundation). A p-value of p<0.05 was considered significant.

Results

Participant demographics

A total of 115 participants were included in this study, of whom 40 received 5 mg/week

of rapamycin, 36 received 10 mg/week of rapamycin, and 39 received placebo (**Supplementary**

Fig S1a). At baseline, all participant groups were comparable across measures of age, sex,

height, weight, BMI, and blood safety markers, with the exception of the mean HbA1C, which

was lower in the 5 mg group than placebo (5mg mean = 5.2%, SD = 0.2; placebo mean = 5.3%,

SD = 0.3; t(72)=2.556, p=0.013; **Table 1**). Overall, participants were in exceptionally good health

at baseline, as evaluated by self-reports of health (**Supplementary Fig S1b**).

Safety: Adverse events

AEs were collected throughout the study as reported by participants on periodic surveys

or through direct contact with investigators (**Supplementary Fig 2a**; see **Table 2** for all AEs). The

most commonly reported AEs were cold/flu/sinus symptoms, musculoskeletal pain, mouth

sores, and malaise, with a greater number of AEs reported in the placebo group relative to

treatment conditions (**Supplementary Fig 2b, Table 2**). The most commonly reported

rapamycin specific AEs were gastrointestinal issues. Surprisingly, mouth sores, which are often

associated with rapamycin treatment [46], were most frequently reported in the placebo group

(placebo: n=27, 5 mg: n=4, 10 mg: n=14; **Table 2**), though the same number of individuals

reported mouth sores in the 10 mg and placebo group (n = 6).

Notably, throughout the length of the trial, participants in the rapamycin treatment

groups reported increased instances of improvements in chronic ailments (chronic issue flare)

that were present when they first entered the trial compared to placebo (placebo: n = 14, 5 mg:

n = 24, 10 mg: n = 28). Conversely, participants in the placebo group reported increased

instances of worsening of their chronic ailments (chronic issue severity) compared to treatment

groups (placebo: n = 12, 5 mg: n = 4, 10 mg: n = 6; **Table 2**). No significant safety-related issues

were detected in the blood work results of any participants during periodic check-ins, or after

the 48 week study period for the 105 participants who completed the entirety of the study

(**Supplementary Table S1**).

Of the 123 total participants enrolled in the study, Serious AEs (SAEs) were reported for

four rapamycin users (three in 5mg group and one in 10mg group) and two placebo users.

Specifically, in the 5 mg group, one participant was hospitalized during the study period due to

respiratory symptoms that seemed related to anemia, which resolved with a blood transfusion.

A second participant in the 5 mg group had a severe infection requiring treatment from their

healthcare provider, which resolved after medication use (prednisone, doxycycline, and

albuterol). The third participant in the 5mg group had a hamstring tear prior to the study, that

healed slowly during the trial. In the 10mg group, a participant reported a sore throat, but

tested positive for group A strep and was prescribed amoxicillin, which resolved the symptoms.

One participant in the placebo group died of myocardial infarction during the study period. A

second participant in the placebo group reported a stomach virus that required attention from

a medical provider, and was diagnosed with small urinary infection. Symptoms resolved after

treatment.

While not an intended endpoint for this study, the study period was during the COVID-

19 pandemic, and a confirmed COVID-19 infection was reported for 25 participants: 10 in the

placebo group (29%), 8 in the 5 mg treatment group (21%), and 7 in the 10 mg treatment group

(21%). Among these, no differences in infection rates, symptom severity, duration of illness, or

length of recovery were noted between groups. Importantly, those with SAEs (described above)

were not noted to have COVID-19 upon physician testing.

Efficacy of rapamycin on healthspan metrics

DEXA Scan results

Participants underwent DEXA scans to assess visceral adipose tissue (VAT) mass, bone

mineral content (BMC), and lean tissue mass (LTM) at three timepoints (baseline, 24, and 48

weeks of treatment) to explore the effects of rapamycin on measures crucial for healthy aging

and the prevention of frailty and disease. At baseline, VAT mass, BMC, and LTM were similar

between the three treatment groups (**Supplementary Table S2**). Over the study period, VAT

mass increased most in the placebo group (mean = +35.34 g, SD = 290.76 g) and decreased in

the group taking 5 mg rapamycin (mean = -39.85 g, SD = 185.18 g), while BMC and LTM

increased only in the 10 mg rapamycin treatment group (BMC: mean = +19.41 g, SD = 104.34;

LTM = 517.87 g, SD = 2440.18). While notable trends of change in body composition measures

from baseline to 48 weeks were observed between treatment groups, none were statistically

significant (linear mixed-effects models interaction: VAT: $F(2, 101.408) = 0.978$,

$p=0.379$; BMC: $F(2,104.415) = 1.403$, $p=0.250$; LTM: $F(2,126.996) = 1.115$, $p=0.331$; BMD:

$F(2,166.294) = 1.596$, $p=0.552$) (**Figure 1a, Supplementary Table S2**). While some changes to

some body composition metrics (e.g. visceral adipose) in rapamycin treatment groups were

observed at 24 weeks, these effects stabilized to measures reported for 48 weeks by the end of

the trial (**Supplementary Fig S3a, Supplementary Table S2**).

As rapamycin has been suggested to have differential effects in males and females, we

explored this possibility by evaluating changes in DEXA scan data across sex (**Table 3**). Analysis

with linear mixed-effects models revealed statistically significant differences in BMC change

between groups across sex (interaction $F(2, 193.245) = 4.489$, $p = 0.012$, **Table 3**), which

subsequent analysis revealed was specifically driven by improvements in the male 10 mg

rapamycin treatment group vs placebo (interaction $F(1, 129.224) = 4.563$, $p = 0.035$, (**Figure 1b**).

This was consistent with changes of bone mineral density (interaction $F(1, 131.924) = 4.956$, $p =$

.028).

Similarly, statistically significant differences in LTM were observed between groups
when assessed across sex (F(2, 206.447) = 5.439, p = 0.005, **Table 3**), which subsequent
analyses revealed were primarily driven by differences between sex in the 10mg rapamycin
treatment group (F(1, 134.554) = 8.880, p = 0.003, **Figure 1c**). Post-hoc within sex analyses
confirmed that gains in LTM over 48 weeks were distinct to female participants taking 10 mg
rapamycin compared to placebo (female 10mg = +1,939.7g (SD = 1,998.9) versus female
placebo = -298.1g (SD = 1,191.1); F(2, 41.242) = 6.423; β = 55.5, SE = 16.9, p = 0.002). This
highlights that the average improvement in LTM in female participants was particularly robust
at an estimated rate of 55.5g per week faster than those on placebo. No significant changes in
BMC and LTM were observed in all other groups, nor were any significant changes in VAT
observed upon subsequent analyses (**Supplementary Fig S3b**).
Notably, marked variability in measures of VAT, LMT, and BMC was observed for all
rapamycin users independent of dose (**Table 3, Supplementary Table S2**). This resulted in
dramatically different impacts for the highest and lowest responding individuals across all
measures for both males and females (**Supplementary Figure S4**). Exploration of raw values of
response for individual participants revealed categories of individuals with improvement and
decline for each body composition measure (**Supplementary Table S2, Figure 2a**). Comparing
across groups, we observed that a greater percentage of individuals in the improvement group
were rapamycin users, with no specific bias in response across all measures by sex (**Figure 2b,**
c). Upon further investigation of individual body composition measures, sex-agnostic rapamycin
associated improvement held true for VAT (**Figure 2d**), however, the percent of participants
showing improvement in BMC and LTM differed by gender (**Figure 2e, f**). This is particularly
notable for BMC, where two thirds of 10mg males showed improvement (**Figure 2e**), and in
LTM, where all of the 10mg female participants demonstrated improvements (**Figure 2f**). Upon
further investigation, we noted that improvements in VAT correlated with
improvements on BMC and LTM, as well as with improved weight and BMI (**Figure 3a**).
Given these findings, we computed a "Benefit Score" for users based on summary
scores of improvement or decline on each body composition measure evaluated by DEXA.
Benefit score was significantly associated with rapamycin use (*t*(44.41) = 2.175, *p* = 0.035),

though some placebo users also saw global improvements and subsequently high Benefit Scores (**Figure 3b**). As our bioavailability study has previously suggested a 3.5x reduction in potency for compounded rapamycin relative to generic, we reasoned that the 10mg group was more likely to be in a relevant bioavailable therapeutic dose range, and thus further investigated Benefit Score in the 10mg vs Placebo groups to explore what might be driving differences in rapamycin response. Importantly, separation of Benefit Scores by rapamycin dose and sex in this manner revealed a pronounced female benefit bias, with all female rapamycin users showing only improvement on the Benefit Score (**Figure 3c**). Subsequent analysis of gut health and blood biomarkers by benefit score revealed significant changes in measures of gut dysbiosis ($F(2,54) = 3.215$, $p = 0.04$; $t(54) = -2.150$, $p = 0.036$), immune readiness ($F(2, 54) = 3.157$, $p = 0.05$; $t(54) = 2.517$, $p = 0.015$; **Figure 3d**), and LDL levels ($F(2, 102) = 4.262$, $p = 0.017$; $t(74) = -2.505$, $p = 0.014$; **Figure 3e**) between high and low Benefit Scores, with rapamycin users showing greater magnitude of beneficial change than placebo.

Blood Biomarkers

In addition to completing routine blood work for safety monitoring, blood biomarkers of health, such as LDL, hemoglobinA1c, triglycerides, and insulin levels were collected throughout the study. While there were no significant differences between groups in biomarkers that were outside the healthy reference range after 48 weeks, significant differences between treatment and control groups were observed for mean change in corpuscular hemoglobin (MCH: 5mg: -0.1 (0.9), 10mg: -0.4 (1.1), Placebo: 0.2 (1.2); F(2, 101) = 3.232, p = 0.040) and mean platelet volume (MPV: 5mg: -0.1 (0.4), 10mg: -0.1 (0.4), Placebo: 0.1 (0.4); F(2, 101 = 4.802, p = 0.10). Post-hoc testing between treatment group pairs revealed additional changes for participants in the 10 mg rapamycin treatment group in chloride levels (10mg: +0.6 (1.5), Placebo: -0.3 (2.0); t(65) = 2.125, p = 0.037), carbon dioxide levels (10mg: -1.2 (1.8), Placebo: -0.4 (2.2); t(65) = 1.786, p = 0.079), and mean corpuscular volume (MCV: 10mg: -1.0 (2.2), Placebo: 0.4 (2.8); t(65)=2.258, p = 0.027), and patients in the 5 mg rapamycin treatment group in platelets (**Supplementary Figure S5a-b, Supplementary Table S1)**. Stratifying by sex did not reveal any additional patterns of significant change between dosing groups and controls over time.

Quality of life

Evaluation of rapamycin's effects on self-reported quality of life (QoL) was conducted

using the SF-36 scale. Baseline measures revealed generally high QoL scores across the study

cohort, with no notable significant differences between groups (overall QoL scores of 83.7

(10.4), 88.1 (7.0), and 84.5 (12.0) for the 5 mg, 10 mg, and placebo groups, respectively, ($F_{(2, 110)}$

= 1.987, p = 0.142; **Supplementary Table S3**). After 48 weeks of treatment most SF-36

scores improved in all groups, however, with the exception of general health (5mg: +5.6 (10.3),

10mg: +3.2 (10.0, Placebo: +0.8 (12.0); $F_{(2, 87)}$ = 4.488, p = 0.014), no statistically significant

changes were detected using marginal linear mixed-effect models between treatment groups

across time (**Supplementary Figure S6a**, **Supplementary Table S3**).

As we observed sex-specific differences in DEXA measures, we similarly evaluated

whether QoL measures differed across sex between the treatment groups over time (mean QoL

scores stratified by sex are presented in **Table 4**). Linear mixed-effect models were employed to

further explore the interaction of sex and treatment groups with change in QoL over time.

Significant longitudinal differences in pain between groups and sex were observed (interaction

$F_{(2, 201.308)}$ = 6.815, p = 0.001), which was driven by a sex difference specifically in the 10 mg

rapamycin treatment group (10mg vs Placebo: $F_{(1, 130.926)}$ = 16.403, p < 0.001, **Figure 4a,b**).

This was confirmed in post-hoc analysis, where specifically females taking 10 mg rapamycin

(+14.7 SD = 13.9) saw improvements in pain compared to placebo (β = 0.332, SE = 0.110, $F_{(1, 6.928)}$

6.928) = 9.121, p = 0.020), indicating that similar to gains in LTM, among females,

improvements in pain are another robust effect of 48 weeks of rapamycin treatment.

Within the 10 mg rapamycin treatment group, the rate of improvement in social

functioning and overall quality of life also showed group and sex differences (**Supplementary**

Table S3), with both social functioning (+12.5 SD = 24.1) and QoL (+5.8 SD = 4.6) improving

most in the 10mg female group (group by sex interaction $F_{(2, 188.862)}$ = 2.701, p = 0.070 and

$F_{(2, 200.291)}$ = 2.028, p = 0.134, respectively). When limiting analyses to 10mg compared to the

placebo group, differences in the rate of improvements in social functioning and quality of life

between group and sex reached significance (interaction $F_{(1, 132.742)}$ = 5.551, p = 0.020 and

F(1, 123.268) = 6.753, p = 0.010, respectively), which, as with pain, appeared to be specifically

driven by females within the 10 mg rapamycin treatment group (**Figure 4a,b**).

Frailty

Finally, we measured symptoms of osteoarthritis (OA) using the WOMAC survey as a

marker for frailty, another important factor defining the length of an individual's healthspan.

Baseline scores were not significantly different across groups (**Supplementary Table S3**), and

linear mixed-effects models again revealed no significant patterns of change in scores across all

groups over the 48-week study period (**Supplementary Figure S6b**). However, given previous

sex-specific effects in other outcome measures, analyses of WOMAC scores were repeated by

exploring differences across sex and groups (**Table 4**). This revealed statistically significant

differences in the WOMAC pain score between groups and sex (interaction F(2, 194.531) =

3.516, p=0.032), with improvements observed particularly for female participants in the 5 mg

and 10 mg rapamycin group (-0.9 SD = 1.8; -0.8 SD = 2.9, respectively; **Figure 4c,d**), and trends

of improvement for the overall frailty score in the same groups (**Supplementary Table S3**;

group by sex interaction F(2, 202.257) = 2.172, p = .117). Evaluation of changes across sex

limited to the 10 mg rapamycin group versus placebo revealed a significant improvement in

both measures (interaction F(1, 120.251) = 5.791, p = 0.018 and F(1, 111.480) = 5,925, p =

0.017, respectively). This highlights that once again, female participants in the 10 mg group

appear to improve most (**Figure 4c,d**). No other significant differences were observed for this

measure.

Discussion

Few clinical trials to date have evaluated the effects of rapamycin and its derivatives in

generally healthy individuals, and those that have been conducted are often challenged by a

small cohort size, short-term follow-up, or both. While the most robust of these studies have

suggested improvements in age-related immune decline in healthy elderly individuals

administered low-dose everolimus for 6 to 16 weeks [41], no study to date has definitively

demonstrated the efficacy of rapamycin for supporting healthy aging in normative aging

individuals. The PEARL trial represents one of the most robust and comprehensive efforts

evaluating the long-term safety and efficacy of low-dose rapamycin for addressing multiple

aspects of age-related decline in a normative aging cohort.

In the current study, no significant differences in markers of metabolic health, liver, and

kidney function, or moderate to severe AEs in the rapamycin treatment groups were reported

compared to placebo after 48 weeks. This is consistent with previous reports summarized in a

review by Maier's group that healthy individuals are not likely to experience serious side effects

from low dose rapamycin, and suggests that concerns over negative effects of rapamycin

stemming from studies of high-dose, daily usage in chronically ill individuals may have limited

applicability in the context of rapamycin use for healthy aging [47]. Indeed, we observed more

instances of individuals reporting improvements in chronic ailments in the rapamycin treatment

groups than in placebo, and more instances reported of worsening ailments in the placebo

group compared to treatment groups after 48 weeks. This effect will be important to

investigate further in longitudinal follow-up with PEARL participants.

While among PEARL participants, those taking 10 mg of rapamycin per week did initially

report more gastrointestinal and neurological AEs (e.g. diarrhea and headaches) compared to

those taking placebo, all (except for one) were acute AEs that resolved on their own, or were

not severe enough to prevent continuation of the rapamycin regimen. Interestingly, despite

well-known impacts of rapamycin on causing mouth sores and a strong association with its

bioavailability and potency [46, 48], participants in the placebo group reported increased

incidents of mouth sores than those in either of the treatment groups, despite the same

number of individuals reporting mouth sores in the 10 mg rapamycin group and placebo (n = 6).

This may be a unique property of compounded rapamycin, though follow-up studies are

currently underway to understand this more comprehensively.

Of note, the PEARL trial was ongoing during the COVID-19 pandemic and rapamycin has

been associated with favorable outcomes in response to SARS-CoV2 [8, 49, 50]. Consistent with

this, we did observe a decreased incidence of COVID-19 reports in the rapamycin treatment

groups (19.7%) compared to placebo (25.6%). Clinical trials are underway that are specifically

designed to more robustly evaluate the efficacy of rapamycin and its derivatives on COVID

outcomes [28-32, 51].

Over the 48 weeks of the study, weekly rapamycin use demonstrated dose-dependent

and sex-specific improvements in multiple functional healthspan metrics compared to placebo,

including lean tissue mass, bone mineral content, pain (SF-36, WOMAC), social functioning (SF-

36), overall quality of life (SF-36), and overall osteoarthritis (WOMAC) score. All statistically

significant benefits were observed in participants taking 10 mg rapamycin per week and

consistent with preclinical reports of a female-benefit bias in mice, female participants

demonstrated significant benefits across all the outcome measures except bone mineral

content [14, 18]. Notably, the most robust improvements observed after 48 weeks were

increases in lean muscle mass within this group. However, as all groups of rapamycin users

(across gender and dose) had individuals that showed large improvements in body composition

measures over time, a summary improvement score accounting for improvement or decline

across all DEXA body composition measures was computed as a Benefit Score. Importantly, all

women taking 10mg of rapamycin had improvements on the Benefit Score, and showed no

declines, whereas men were represented in both groups. Across all participants, those with

high benefit scores had significant improvements in gut health measures of gut dysbiosis and

immune readiness, and in LDL levels relative to those with low benefit scores. Greater

responses on these measures were observed for rapamycin users than placebo users. Taken

together, these findings suggest that digestive health, diet, and/or microbiome may play a

significant role in rapamycin response and subsequent likelihood of benefits, and will be a focus

of our future work.

Findings from this study that male participants in the 10 mg rapamycin group gained an

average of 1.4% BMC over 48 weeks and female participants in the 10 mg group gained an

average LTM of 4.5% hold significant promise for rapamycin in reducing risks of age-related

disease and mortality. This is particularly true for the highest rapamycin responding individuals,

who exhibit greater improvements in body composition than typical for individuals of this trial

age cohort. For example, one female participant in the 10 mg rapamycin group exhibited a 19%

improvement in lean muscle mass over the 48 week period, and another saw a 15% increase in

BMC over two years of taking rapamycin consistently during and post-trial. Given the expected

worsening of body composition metrics each year after the age of 60, which have a

compounding influence on the risk of age-related adverse outcomes, rapamycin clearly has an

important role as a gerotherapeutic in the future of healthy longevity medicine

While this trial extended notably longer than other human trials of rapamycin use for

healthy longevity to date, it is likely that even greater effects would be observed with an

increased observation period, a broader (specifically higher) range of doses, as well as a larger

study cohort. Further, while it was outside the scope of this study to determine all sources of

variability, there are several lifestyle factors (such as diet, alcohol consumption, sleep quality,

and activity levels) that may influence VAT, LTM, and BMC changes over time [52, 53], and

which may have yet-to-be-identified impacts on rapamycin bioavailability that would add value

to future studies on this topic.

Across all measures in this study, a remarkable level of variability in response was

observed for all rapamycin users, regardless of dose. Given our recent work on the variability of

rapamycin bioavailability in individuals, we expect that it played a meaningful role in the results

observed here, though this trial concluded prior to our findings on bioavailability. Further, we

have discovered since the conclusion of this trial that compounded rapamycin is approximately

3.5x less bioavailable than commercially available formulations, suggesting that the 5mg and

10mg rapamycin groups received an average equivalent of 1.4mg and 2.9mg respectively [48].

Although both doses are relatively low, making the observation of benefits in the treatment

group more striking, the 10mg rapamycin cohort in this study was more firmly in the range of

what is thought to be an optimal longevity dose range for rapamycin [8, 41, 47, 54]. While

future studies will be necessary to draw clear conclusions on whether even higher doses lead to

improved effects, we expect that this is a key factor in the often stronger and more reliable

patterns of improvement seen for the 10mg rapamycin cohort relative to the 5mg cohort. We

highlight this to emphasize the importance of personalized rapamycin dosing and continual

routine monitoring of blood rapamycin levels in users to ensure maximal benefits, until such

time as the optimal longevity dosing dynamics for rapamycin are more clearly understood.

Beyond physical measures of rapamycin impacts explored in this study, self-reported

measures of perceived health and quality of life also showed improvement for all groups. This is

especially important in a normative aging population, still in their healthspan, as evaluating

changes in QoL captures multiple dimensions of health and functioning that both precede and

go beyond disease progression alone. As maintaining an active, pain-free, high quality of life

(QoL) in aging is one of the most important aspects of healthspan, findings from the current

study that rapamycin users had improved scores on multiple measures of the well-established

SF-36 and WOMAC scales are particularly promising. While a female-benefit bias was noted for

both measures, significant improvements were observed only for the female 10mg rapamycin

group. This is consistent with previous findings in a cohort of 333 adults using off-label

rapamycin for healthy aging in which rapamycin was associated with increased reports of

happiness, brain function, feelings of youthfulness, calm, reduced anxiety and pain compared

to non-users in that same timeframe (up to 10 years for some participants) [8].

Of particular note, with PEARL, we are the first to show that 10 mg rapamycin/week for

48 weeks has a modest but significant benefit on osteoarthritis symptoms, specifically in

women, based on the WOMAC clinical OA assessment. As our study was within a normative

aging population, small improvements in early age-related progression of OA could lead to

substantial cumulative benefits over time on frailty outcomes [55, 56]. Despite this, follow-up

studies are required to determine why males did not demonstrate similar OA associated

benefits in this study, and what additional adjustments or considerations would be required for

men to derive similar OA related benefits.

Conclusion

The PEARL trial is the largest and longest decentralized RCT evaluating the safety and efficacy of

low, intermittent "longevity doses" of rapamycin on healthy aging through the measurement of

clinically relevant healthspan metrics. Our findings provide evidence that low dose, intermittent

rapamycin regimens are well tolerated and do not lead to any serious adverse events or clinical

abnormalities when administered for at least one year within normative aging individuals.

Beyond this, we observed benefits for rapamycin users in the PEARL trial, as measured by

significant improvements in lean muscle mass, pain, social functioning, frailty outcomes, and

overall quality of life in females, and improved bone mineral density in males. Further, there

were some individuals in the rapamycin treatment groups that experienced large

improvements in body composition metrics after 48 weeks, which were further associated with

beneficial changes in gut health and LDL levels. Future work will more comprehensively explore

what drives high response rates to rapamycin, and will aim to identify biometric signatures that

can be used to predict clinical effectiveness and inform personalized treatment strategies.

As our previous investigation on the bioavailability of rapamycin suggests no significant

differences between men and women, further investigation in to mediators of sex specific

effects of rapamycin are warranted to elucidate what role factors such as differences in

hormone signaling, growth factor signaling, mTOR signaling activity, genetic polymorphisms, or

other factors meaningfully contribute to the sex-specific effects we observed in this study, and

particularly the female-benefit bias we observed for most measures. While the current report

details the primary endpoints for the PEARL trial, many PEARL participants continue to take

longevity doses of rapamycin, and have consented to share ongoing information. Reports on

these longitudinal studies will be released publicly as available, in keeping with our strong

conviction that freely permitting combinatory result analyses will allow for better

understanding of optimal dosing, safety, changes in aging biomarkers, and overlapping

outcomes for this important gerotherapeutic intervention.

Collectively, the PEARL clinical trial is one of the first to provide evidence that low-dose

rapamycin may be safely administered for extended periods of time and may counteract

several aspects of age-related decline. Further, it represents the first study indicating dose-

dependent, sex specific efficacy for rapamycin in improving healthspan metrics in humans. As

such, our collective evidence suggests that well beyond merely clinical measures of health

improvements, rapamycin may promote essential, comprehensive well-being associated with

"adding life to years, not just years to life".

Statements and Declarations:

Acknowledgements

The authors would like to thank the participants who took part in this study. Financial support from our generous donors, particularly Vitalik Buterin, Micah Zoltu, Brad Armstrong, and anonymous gifts, administrative support, and article publishing charges were provided by AgelessRx. Clinical trial oversight was conducted by PHAGE corporation. We extend special thanks to Mikhail Blagosklonny, James Watson, Alan Green and Thorne for their participation and support in conducting this trial.

Competing interests

GH, VL, AN, MM, SM, AI, and SZ are employees and shareholders of AgelessRx. JH has received financial compensation from AgelessRx for their contributions.

Author contributions

Virginia Lee, Andy Nyquist, Anar Isman, and Sajad Zalzala designed and implemented the study. Girish Harinath, Jesper Hagemeier, and Stefanie Morgan performed data analysis. Girish Harinath, Virginia Lee, Andy Nyquist, Mauricio Moel, Stefanie Morgan, Anar Isman, and Sajad Zalzala wrote and edited the manuscript. All work was supervised by Stefanie Morgan, Anar Isman, and Sajad Zalzala. Corresponding author is Stefanie Morgan.

References

1.   Al-Maskari F. LIFESTYLE DISEASES: An Economic Burden on the Health Services. UN Chronicle [Internet]. [cited 2024 August]. Available from: https://www.un.org/en/chronicle/article/lifestyle-diseases-economic-burden-health-services#:~:text=By%202030%2C%20the%20proportion%20of,African%20and%20Eastern%20Mediterranean%20regions.

2.   Ford ES, Bergmann Mm Fau - Kröger J, Kröger J Fau - Schienkiewitz A, Schienkiewitz A Fau - Weikert C, Weikert C Fau - Boeing H, Boeing H. Healthy living is the best revenge: findings

from the European Prospective Investigation Into Cancer and Nutrition-Potsdam study. (1538-
3679 (Electronic))

3. Kvaavik E, Batty Gd Fau - Ursin G, Ursin G Fau - Huxley R, Huxley R Fau - Gale CR, Gale
CR. Influence of individual and combined health behaviors on total and cause-specific mortality
in men and women: the United Kingdom health and lifestyle survey. (1538-3679 (Electronic))

4. Coe E, Dewhurst M, Hartenstein L, Hextall A, Latkovic T. At least six years of higher
quality life for everyone is within reach. Adding years to life and life to years [Internet]. 2022
[cited 2024 August]. Available from: https://www.mckinsey.com/mhi/our-insights/adding-
years-to-life-and-life-to-years.

5. Garmany A, Yamada S, Terzic A. Longevity leap: mind the healthspan gap. NPJ Regen
Med. 2021;6(1):57 https://doi.org/10.1038/s41536-021-00169-5.

6. Sierra F. The Emergence of Geroscience as an Interdisciplinary Approach to the
Enhancement of Health Span and Life Span. (2157-1422 (Electronic))

7. Kulkarni AS, Aleksic S, Berger DM, Sierra F, Kuchel GA, Barzilai N. Geroscience-guided
repurposing of FDA-approved drugs to target aging: a proposed process and prioritization.
Aging Cell. 2022;21(4):e13596 https://doi.org/10.1111/acel.13596.

8. Kaeberlein TL, Green AS, Haddad G, Hudson J, Isman A, Nyquist A, et al. Evaluation of
off-label rapamycin use to promote healthspan in 333 adults. Geroscience. 2023;45(5):2757-68
https://doi.org/10.1007/s11357-023-00818-1.

9. Mannick JB, Lamming DW. Targeting the biology of aging with mTOR inhibitors. Nat
Aging. 2023;3(6):642-60 https://doi.org/10.1038/s43587-023-00416-y.

10. Chung J, Kuo Cj Fau - Crabtree GR, Crabtree Gr Fau - Blenis J, Blenis J. Rapamycin-FKBP
specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein
kinases. (0092-8674 (Print))

11. Castilho RM, Squarize Ch Fau - Chodosh LA, Chodosh La Fau - Williams BO, Williams Bo
Fau - Gutkind JS, Gutkind JS. mTOR mediates Wnt-induced epidermal stem cell exhaustion and
aging. (1875-9777 (Electronic))

12.   Urfer SR, Kaeberlein TL, Mailheau S, Bergman PJ, Creevy KE, Promislow DEL, et al. A

randomized controlled trial to establish effects of short-term rapamycin treatment in 24

middle-aged companion dogs. GeroScience. 2017;39(2):117-27 10.1007/s11357-017-9972-z.

13.   Robida-Stubbs S, Glover-Cutter K Fau - Lamming DW, Lamming Dw Fau - Mizunuma M,

Mizunuma M Fau - Narasimhan SD, Narasimhan Sd Fau - Neumann-Haefelin E, Neumann-

Haefelin E Fau - Sabatini DM, et al. TOR signaling and rapamycin influence longevity by

regulating SKN-1/Nrf and DAF-16/FoxO. (1932-7420 (Electronic))

14.   Miller RA, Harrison De Fau - Astle CM, Astle Cm Fau - Fernandez E, Fernandez E Fau -

Flurkey K, Flurkey K Fau - Han M, Han M Fau - Javors MA, et al. Rapamycin-mediated lifespan

increase in mice is dose and sex dependent and metabolically distinct from dietary restriction.

(1474-9726 (Electronic))

15.   Juricic P, Lu Y-X, Leech T, Drews LF, Paulitz J, Lu J, et al. Long-lasting geroprotection from

brief rapamycin treatment in early adulthood by persistently increased intestinal autophagy.

Nature Aging. 2022;2(9):824-36 10.1038/s43587-022-00278-w.

16.   Bitto A, Ito TK, Pineda VV, LeTexier NJ, Huang HZ, Sutlief E, et al. Transient rapamycin

treatment can increase lifespan and healthspan in middle-aged mice. eLife. 2016;5:e16351

10.7554/eLife.16351.

17.   Barnett BG, Wesselowski SR, Gordon SG, Saunders AB, Promislow DEL, Schwartz SM, et

al. A masked, placebo-controlled, randomized clinical trial evaluating safety and the effect on

cardiac function of low-dose rapamycin in 17 healthy client-owned dogs. (2297-1769 (Print))

18.   Arriola Apelo SI, Pumper CP, Baar EL, Cummings NE, Lamming DW. Intermittent

Administration of Rapamycin Extends the Life Span of Female C57BL/6J Mice. (1758-535X

(Electronic))

19.   Powers RW, 3rd, Kaeberlein M Fau - Caldwell SD, Caldwell Sd Fau - Kennedy BK,

Kennedy Bk Fau - Fields S, Fields S. Extension of chronological life span in yeast by decreased

TOR pathway signaling. (0890-9369 (Print))

20.   Colman RJ, Anderson Rm Fau - Johnson SC, Johnson Sc Fau - Kastman EK, Kastman Ek

Fau - Kosmatka KJ, Kosmatka Kj Fau - Beasley TM, Beasley Tm Fau - Allison DB, et al. Caloric

restriction delays disease onset and mortality in rhesus monkeys. (1095-9203 (Electronic))

21.   Harrison DE, Strong R Fau - Sharp ZD, Sharp Zd Fau - Nelson JF, Nelson Jf Fau - Astle CM,

Astle Cm Fau - Flurkey K, Flurkey K Fau - Nadon NL, et al. Rapamycin fed late in life extends

lifespan in genetically heterogeneous mice. (1476-4687 (Electronic))

22.   Miller RA, Harrison DE, Astle CM, Baur JA, Boyd AR, de Cabo R, et al. Rapamycin, But Not

Resveratrol or Simvastatin, Extends Life Span of Genetically Heterogeneous Mice. The Journals

of Gerontology: Series A. 2011;66A(2):191-201 10.1093/gerona/glq178.

23.   Flynn JM, O'Leary Mn Fau - Zambataro CA, Zambataro Ca Fau - Academia EC, Academia

Ec Fau - Presley MP, Presley Mp Fau - Garrett BJ, Garrett Bj Fau - Zykovich A, et al. Late-life

rapamycin treatment reverses age-related heart dysfunction. (1474-9726 (Electronic))

24.   Selvarani R, Mohammed S, Richardson A. Effect of rapamycin on aging and age-related

diseases-past and future. Geroscience. 2021;43(3):1135-58 https://doi.org/10.1007/s11357-

020-00274-1.

25.   Zhang Y, Zhang J, Wang S. The role of rapamycin in healthspan extension via the delay of

organ aging. Ageing Res Rev. 2021;70:101376 https://doi.org/10.1016/j.arr.2021.101376.

26.   RapAdmin. Breaking: 15% Healthy Lifespan improvement via Rapamycin seen in

Marmosets 2024 [Available from: https://www.rapamycin.news/t/breaking-15-healthy-

lifespan-improvement-via-rapamycin-seen-in-marmosets/14325.

27.   Weston AD, Grossardt BR, Garner HW, Kline TL, Chamberlain AM, Allen AM, et al.

Abdominal body composition reference ranges and association with chronic conditions in an

age- and sex-stratified representative sample of a geographically defined American population.

J Gerontol A Biol Sci Med Sci. 2024;79(4) https://doi.org/10.1093/gerona/glae055.

28.   Hunter GR, Gower BA, Kane BL. Age related shift in visceral fat. Int J Body Compos Res.

2010;8(3):103-8

29.   Volpi E, Nazemi R, Fujita S. Muscle tissue changes with aging. Curr Opin Clin Nutr Metab

Care. 2004;7(4):405-10 https://doi.org/10.1097/01.mco.0000134362.76653.b2.

30.   Whitaker KM, Choh AC, Lee M, Towne B, Czerwinski SA, Demerath EW. Sex differences

in the rate of abdominal adipose accrual during adulthood: the Fels Longitudinal Study. Int J

Obes (Lond). 2016;40(8):1278-85 https://doi.org/10.1038/ijo.2016.48.

31.   Berger C, Langsetmo L, Joseph L, Hanley DA, Davison KS, Josse R, et al. Change in bone

mineral density as a function of age in women and men and association with the use of

antiresorptive agents. CMAJ. 2008;178(13):1660-8 https://doi.org/10.1503/cmaj.071416.

32.   Alswat KA. Gender disparities in osteoporosis. J Clin Med Res. 2017;9(5):382-7

https://doi.org/10.14740/jocmr2970w.

33.   Mikkola TM, Kautiainen H, von Bonsdorff MB, Salonen MK, Wasenius N, Kajantie E, et al.

Body composition and changes in health-related quality of life in older age: a 10-year follow-up

of the Helsinki Birth Cohort Study. Qual Life Res. 2020;29(8):2039-50

https://doi.org/10.1007/s11136-020-02453-1.

34.   Chlabicz M, Dubatowka M, Jamiolkowski J, Sowa P, Lapinska M, Raczkowski A, et al.

Subjective well-being in non-obese individuals depends strongly on body composition. Sci Rep.

2021;11(1):21797 https://doi.org/10.1038/s41598-021-01205-6.

35.   Lin H, Salech F, Lim A, Vogrin S, Duque G. The effect of rapamycin and its analogues on

age-related musculoskeletal diseases: a systematic review. Aging Clin Exp Res.

2022;34(10):2317-33 https://doi.org/10.1007/s40520-022-02190-0.

36.   den Hartigh LJ, Goodspeed L, Wang SA, Kenerson HL, Omer M, O'Brien KD, et al. Chronic

oral rapamycin decreases adiposity, hepatic triglycerides and insulin resistance in male mice fed

a diet high in sucrose and saturated fat. Exp Physiol. 2018;103(11):1469-80

https://doi.org/10.1113/EP087207.

37.   Konopka AR, Lamming DW, Investigators RP, Investigators E. Blazing a trail for the

clinical use of rapamycin as a geroprotecTOR. Geroscience. 2023;45(5):2769-83

https://doi.org/10.1007/s11357-023-00935-x.

38.   Mannick JB, Del Giudice G, Lattanzi M, Valiante NM, Praestgaard J, Huang B, et al. mTOR

inhibition improves immune function in the elderly. (1946-6242 (Electronic))

39.   Mannick JB, Morris M, Hockey H-UP, Roma G, Beibel M, Kulmatycki K, et al. TORC1

inhibition enhances immune function and reduces infections in the elderly. Science

Translational Medicine. 2018;10(449):eaaq1564 10.1126/scitranslmed.aaq1564.

40.   Mannick JB, Teo G, Bernardo P, Quinn D, Russell K, Klickstein L, et al. Targeting the

biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b

and phase 3 randomised trials. (2666-7568 (Electronic))

41.   Mannick JB, Morris M, Hockey HP, Roma G, Beibel M, Kulmatycki K, et al. TORC1

inhibition enhances immune function and reduces infections in the elderly. Sci Transl Med.

2018;10(449) https://doi.org/10.1126/scitranslmed.aaq1564.

42.   Walters HE, Cox LS. mTORC inhibitors as broad-spectrum therapeutics for age-related

diseases. Int J Mol Sci. 2018;19(8) https://doi.org/10.3390/ijms19082325.

43.   Viscomi MT, D'Amelio M, Cavallucci V, Latini L, Bisicchia E, Nazio F, et al. Stimulation of

autophagy by rapamycin protects neurons from remote degeneration after acute focal brain

damage. Autophagy. 2012;8(2):222-35 10.4161/auto.8.2.18599.

44.   Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I.

Conceptual framework and item selection. (0025-7079 (Print))

45.   Riddle DL, Perera RA. The WOMAC pain scale and crosstalk from co-occurring pain sites

in people with knee pain: A causal modeling study. Phys Ther. 2020;100(10):1872-81

https://doi.org/10.1093/ptj/pzaa098.

46.   Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, et al. Oral

mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on

pathobiology and impact on clinical practice. Cancer Med. 2016;5(8):1897-907

https://doi.org/10.1002/cam4.761.

47.   Lee DJW, Hodzic Kuerec A, Maier AB. Targeting ageing with rapamycin and its

derivatives in humans: a systematic review. Lancet Healthy Longev. 2024;5(2):e152-e62

https://doi.org/10.1016/S2666-7568(23)00258-1.

48.   Harinath G, Lee V, Nyquist A, Moel M, Wouters M, Hagemeier J, et al. The bioavailability

of compounded and generic rapamycin in normative aging individuals: A retrospective study

and review with clinical implications. MedRxiv. 2024

https://doi.org/10.1101/2024.08.12.24311432.

49.   Patocka J, Kuca K, Oleksak P, Nepovimova E, Valis M, Novotny M, et al. Rapamycin: Drug

Repurposing in SARS-CoV-2 Infection. Pharmaceuticals (Basel). 2021;14(3)

https://doi.org/10.3390/ph14030217.

50.   Singla A, Harun N, Dilling DF, Merchant K, McMahan S, Ingledue R, et al. Safety and

efficacy of sirolimus in hospitalised patients with COVID-19 pneumonia. Respir Investig.

2024;62(2):216-22 https://doi.org/10.1016/j.resinv.2023.12.009.

51.   Bischof E, Siow RC, Zhavoronkov A, Kaeberlein M. The potential of rapalogs to enhance

resilience against SARS-CoV-2 infection and reduce the severity of COVID-19. Lancet Healthy

Longev. 2021;2(2):e105-e11 https://doi.org/10.1016/S2666-7568(20)30068-4.

52.   Lv X, Cai J, Li X, Wang X, Ma H, Heianza Y, et al. Body composition, lifestyle, and

depression: a prospective study in the UK biobank. BMC Public Health. 2024;24(1):393

https://doi.org/10.1186/s12889-024-17891-6.

53.   United States. Public Health Service. Office of the Surgeon General. 6 Determinants of

bone health. Bone health and osteoporosis : a report of the Surgeon General. Rockville, Md.:

U.S. Dept. of Health and Human Services, Public Health Service, Office of the Surgeon General;

2004. p. xxxii, 404 p.

54.   Blagosklonny MV. Rapamycin for longevity: opinion article. Aging (Albany NY).

2019;11(19):8048-67 https://doi.org/10.18632/aging.102355.

55.   Puts MT, Toubasi S, Atkinson E, Ayala AP, Andrew M, Ashe MC, et al. Interventions to

prevent or reduce the level of frailty in community-dwelling older adults: a protocol for a

scoping review of the literature and international policies. BMJ Open. 2016;6(3):e010959

https://doi.org/10.1136/bmjopen-2015-010959.

56.   Apostolo J, Cooke R, Bobrowicz-Campos E, Santana S, Marcucci M, Cano A, et al.

Effectiveness of interventions to prevent pre-frailty and frailty progression in older adults: a

systematic review. JBI Database System Rev Implement Rep. 2018;16(1):140-232

https://doi.org/10.11124/JBISRIR-2017-003382.

Figure Legends

Figure 1. Effects of rapamycin use on changes in measures of body composition. Notable trends of change in body composition from baseline to 48 weeks were observed between treatment groups for all subjects (a). Analysis of changes in body composition measures within sex revealed that bone mineral content improved significantly for men taking 10mg rapamycin (b) as did lean tissue mass for females taking 10mg rapamycin (c). *p <0.05, **p ≤ 0.005

Figure 2. Heterogeneity in rapamycin response reveals differential patterns of effects. Within all study arms, individual participants showed marked improvement and decline for each measure of body composition (a). A greater percentage of individuals in the improvement group were rapamycin users (b), with no specific bias in response across all measures by sex (c). Similar trends were observed for measures of VAT (d), however, BMC (e), and LTM (f) showed sex-specific improvement and decline.

Figure 3. Rapamycin response categorized by Benefit Scores revealed biological change differences by response type. Improvements in VAT correlated with improvements on BMC and LTM, as well as with improved weight and BMI (a). A "Benefit Score" was computed for users based on summary scores of improvement or decline on each body composition measure evaluated by DEXA, which was significantly associated with rapamycin use (b). Separation of Benefit Scores by rapamycin dose and sex revealed a pronounced female benefit bias, with only improvement for all female rapamycin users (c). Subsequent analysis of gut health and blood biomarkers by benefit score revealed significant changes in measures of gut dysbiosis, immune readiness (d), and LDL levels (e) between high and low Benefit Scores, with greater magnitude of beneficial change for rapamycin users than placebo.

Figure 4. Effects of rapamycin use on quality of life and frailty. Quality of life measures from the SF-36 showed improvements across most measures for female rapamycin users (a), with statistically significant improvements in scores of pain, social functioning, and overall quality of life. Male rapamycin users showed only trends of improvement for many measures, particularly

for the 5mg cohort (b). Similar patterns were seen for frailty measures from the WOMAC scale,

with female rapamycin users showing improvements across most measures, and significant

improvements in pain and overall frailty (c). In contrast, male rapamycin users did not show

improvements on WOMAC scores relative to controls (d).

Supplementary Figure S1. PEARL trial design and participant health scores. Schematic of trial

enrollment, participant screening, randomization, and followup (a), and a summary of all

participants health scores (b) highlighting significant baseline health of participants in this

study.

Supplementary Figure S2. Adverse events and types for PEARL participants. A summary of

adverse event types by trial arm showed no rapamycin-specific adverse event patterns (a).

Further investigation of adverse event types revealed similar effects for all trial arms, with the

exception of a higher proportion of gastrointestinal events reported for rapamycin users than

controls (b).

Supplementary Figure S3. Effects of rapamycin use on sex-specific changes in measures of

body composition over time. Change in body composition measures at the study midpoint (24

weeks) showed evidence of some measure of change (a) that largely stabilized to the patterns

reported after 48 weeks. Change at 48 weeks of VAT, and of BMC in females and LTM in males

did not show statistically significant improvements for rapamycin users relative to controls (b).

Supplementary Figure S4. Heterogeneity of rapamycin response in body composition

measures. Within trial arms, notable differences in participant responses were observed across

all measures, with sex-specific differences in proportion of participants improving or declining

for most measures.

Supplementary Figure S5. Changes in blood biomarkers in response to rapamycin use. While

no significant differences in biomarkers were outside the healthy reference range after 48

weeks, significant differences between treatment and control groups were observed for mean

change in corpuscular hemoglobin (MCH) and mean platelet volume (MPV), and for the 10 mg

rapamycin group in chloride levels, carbon dioxide levels, and mean corpuscular volume (MCV),

and patients in the 5 mg rapamycin treatment group in platelets (a). No statistically significant

changes were seen for other biomarkers (b).

Supplementary Figure S6. Effects of rapamycin use on quality of life and frailty measures

across groups. After 48 weeks of treatment most SF-36 scores of perceived Quality of Life

improved in all groups (a), as did WOMAC scores of frailty (b).

     Tables

Table 1: Baseline demographics and blood safety markers

	5 mg N=40 Mean (SD)	10 mg N=36 Mean (SD)	Placebo N=39 Mean (SD)	F(df1, df2)	p-value
Age (years)	61.2 (7.6)	62.4 (9.1)	62.6 (6.6)	0.425(2, 112)	0.655
Sex (Female) N (%)	17 (42.5)	9 (25.0)	15 (38.5)	χ^2=2.732(2)	0.255
Height (cm)	171.9 (10.0)	176.2 (9.0)	175.0 (9.1)	1.940(2, 101)	0.149
Weight (kg)	75.6 (15.3)	80.1 (13.6)	75.2 (14.5)	1.263(2, 105)	0.287
BMI (kg/m^2)	25.2 (3.5)	25.6 (3.3)	24.3 (3.0)	1.407 (2, 100)	0.250
Glucose (mg/dL)	90.9 (3.5)	92.1 (8.8)	91.5 (11.1)	0.160(2, 112)	0.852
LDL cholesterol (mg/dL)	107.8 (34.4)	104.3 (39.5)	115.1 (32.4)	0.921(2, 112)	0.401
Non-HDL cholesterol (mg/dL)	119.4 (37.4)	121.6 (43.5)	134.2 (34.5)	1.683(2, 112)	0.191
Triglycerides (mg/dL)	86.2 (32.4)	90.0 (39.8)	92.8 (45.8)	0.280(2, 112)	0.756
HbA1c (%)	5.2 (0.2)	5.3 (0.2)	5.3 (0.3)	3.418(2, 106)	**0.036***
Insulin (uIU/mL)	5.8 (5.2)	6.1 (4.2)	5.0 (3.2)	0.528(2, 110)	0.528
ALT (U/L)	22.1 (10.8)	23.4 (9.0)	22.4 (12.9)	0.141(2, 112)	0.869
AST (U/L)	22.7 (7.2)	23.4 (5.3)	22.6 (6.7)	0.154(2, 112)	0.857
BUN (mg/dL)	16.8 (4.9)	15.8 (2.9)	16.3 (4.4)	0.487(2, 112)	0.616
Creatinine (mg/dL)	0.9 (0.2)	1.0 (1.2)	1.0 (0.3)	1.045(2, 112)	0.355
eGFR (mL/min/1.73m^2)	85.4 (14.1)	83.0 (10.8)	79.1 (15.3)	2.007(2, 108)	0.139

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation.
Groups were compared using Analysis of Variance and post-hoc independent t-test. *$p < 0.05.$

Table 2: Self-reported adverse events during study period

	5 mg	10 mg	Placebo
Cardiovascular			
-Cardiological event	-	-	1 (2.6%) 1
-Discomfort/Tightness in chest	1 (2.5%) 1	-	-
Gastrointestinal			
-Lower gastrointestinal symptoms	4 (10%) 5	6 (16.7%) 9	3 (7.7%) 3
-Upper and lower gastrointestinal symptoms	3 (7.5%) 3	1 (2.8%) 2	1 (2.6%) 1
-Upper gastrointestinal symptoms	2 (5%) 5	3 (8.3%) 4	-
Musculoskeletal and Orthopedic			
-Musculoskeletal pain	10 (25%) 19	12 (33.3%) 20	11 (28.2%) 20
-Deep tissue injury (closed)	1 (2.5%) 2	-	1 (2.6%) 1
-Musculoskeletal/Orthopedic injury (closed)	1 (2.5%) 1	-	1 (2.6%) 1
Neurological			
-Altered spatial orientation	1 (2.5%) 1	3 (8.3%) 7	2 (5.1%) 3
-Cognitive decline	-	1 (2.8%) 1	-
-Neuromuscular symptoms	-	1 (2.8%) 1	2 (5.1%) 2
Oral and Dental			
-Mouth sores	3 (7.5%) 4	6 (16.7%) 14	6 (15.4%) 27
-Dental symptoms	2 (5%) 3	2 (5.6%) 2	1 (2.6%) 1
Respiratory			
-Cold/Flu/Sinus symptoms	23 (57.5%) 35	19 (52.8%) 29	22 (56.4%) 33
-Respiratory symptoms	1 (2.5%) 2	-	-
Sensory			
-Auditory perception symptoms	2 (5%) 2	3 (8.3%) 3	2 (5.1%) 2
-Visual perception symptoms	1 (2.5%) 1	1 (2.8%) 1	-
Skin and Wound			
-Superficial wound/Skin irritation	6 (15%) 8	7 (19.4%) 11	9 (23.1%) 12
-Deep wound (opened)	-	-	2 (5.1%) 2
-Skin bacterial/fungal infection	1 (2.5%) 1	-	2 (5.1%) 2
Urinary, Kidney, and Reproductive			
-Kidney/Urinary symptoms	4 (10%) 5	2 (5.6%) 2	2 (5.1%) 2

-Menopausal symptoms	1 (2.5%) 1	1 (2.8%) 1	2 (5.1%) 2
Other			
-Erectile dysfunction	-	1 (2.8%) 1	-
-Malaise	3 (7.5%) 11	2 (5.6%) 2	1 (2.6%) 1
-Eye infection/disorder	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Mental Health Symptoms	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Pain (not otherwise specified)	1 (2.5%) 1	1 (2.8%) 1	1 (2.6%) 1
-Sleep disturbances	-	1 (2.8%) 1	-
Chronic Issue Flare	12 (30%) 23	13 (36.1%) 28	10 (25.6%) 14
Chronic Issue Severity	4 (10%) 4	4 (11.1%) 6	4 (10.3%) 12

*Includes all reported events by the cohort. Some participants had multiple events or experienced the same events multiple times. Adverse events reported as: n participants (%) n events. Chronic issue flare: participants entered the PEARL trial with a chronic ailment which improved or stayed the same during the trial. Chronic issue severity: participants entered the PEARL trial with a chronic ailment that worsened during the trial.

Table 3: Dexa baseline output and change after 48 weeks, stratified by sex

Baseline

Values for Females, *Males*	5 mg	10 mg	Placebo	**Changes by sex** F(df1, df2)†	p-value†	**Changes by group** F(df1, df2) ‡	p-value ‡
Visceral adipose tissue mass (g)	500.6 (449.7)	407.0 (346.2)	518.2 (321.5)	F(2, 37) = 0.231	0.795	F(5, 107) = 5.426	< 0.001
	1321.2 (995.0)	*1203.7 (810.4)*	*1084.3 (690.4)*	*F(2, 70) = 0.470*	*0.627*		
Bone mineral content (g)	2174.4 (245.6)	2422.7 (490.6)	2196.6 (239.8)	F(2, 35) = 1.885	0.167	F(5, 101) = 22.304	< 0.001
	3059.9 (492.9)	*3048.9 (397.4)*	*3243.7 (529.9)*	*F(2, 66) = 1.242*	*0.295*		
Lean tissue mass (g)	39313.1 (5098.6)	41231.8 (8112.7)	38983.8 (3769.5)	F(2 ,37) = 0.488	0.618	F(5, 106) = 44.559	< 0.001
	58290.8 (6084.4)	*58864.5 (7178.5)*	*59950.8 (8154.6)*	*F(2, 69) = 0.317*	*0.729*		
Bone Mineral Density (g/cm2)	1.1210 (0.1182)	1.1951 (0.1799)	1.1035 (0.0838)	F(2, 35) = 1.537	0.229	F(5, 103) = 8.983	< 0.001
	1.2558 (0.1750)	*1.3006 (0.1228)*	*1.3397 (0.1341)*	*F(68) = 1.890*	*0.159*		

Change from baseline – 48 weeks

	5 mg	10 mg	Placebo	F(df1, df2)†	p-value†	F(df1, df2) ‡	p-value ‡
Visceral adipose tissue mass (g)	-29.3 (170.6)	-6.1 (116.2)	50.7 (69.3)	F(2,34.546) = 1.294	0.287	F(2, 203.934) = 0.854	0.427
	-48.6 (201.0)	*19.2 (277.4)*	*26.9 (362.6)*	*F(2. 127.416) = 0.329*	*0.72*		

Bone mineral content (g)	-19.8 (64.4)	-50.6 (106.8)	-23.1 (82.0)	$F(2, 43.111) = 0.251$	0.779	$F(2, 193.245) = 4.489$	0.012
	-41.7 (95.2)	*45.2 (93.3)*	*-0.7 (100.6)*	*$F(2, 70.240) = 2.249$*	*0.113*		
Lean tissue mass (g)	-60.6 (1613.8)	1939.7 (1998.9)	-298.1 (1191.1)	$F(1,70.369) = 1.022$	0.004	$F(2, 206.447) = 5.439$	0.005
	-68.6 (3034.7)	*-6.0 (2421.2)*	*-525.1 (2138.6)*	*$F(2, 80.616) = 0.112$*	*0.894*		
Bone Mineral Density (g/cm2)	-0.0114 (0.0195)	-0.0100 (0.0325)	-0.0021 (0.0332)	$F(2,43.316) = 1.461$	0.243	$F(2, 163.750) = 1.673$	0.191
	0.0463 (0.2108)	*0.0046 (0.0361)*	*-0.0012 (0.0267)*	*$F(2, 109.733) = 1.006$*	*0.369*		

858 *Values provided as mean (standard deviation). Groups were compared using Analysis of Variance (baseline)*
859 *and linear mixed effects model (change from week 0 through 48) by sex and group.*
860

Table 4: Baseline SF-36 and WOMAC and absolute change at 48 weeks, stratified by sex

	Women			Men		
	5 mg	10 mg	Placebo	5 mg	10 mg	Placebo
Baseline						
SF-36						
- Physical functioning	95.3 (6.2)	96.1 (4.2)	93.0 (10.7)	94.6 (8.3)	95.6 (9.8)	95.5 (8.7)
- Physical role limitations	92.7 (14.7)	94.4 (11.0)	83.3 (32.3)	94.6 (21.3)	95.4 (12.1)	90.9 (23.8)
- Emotional role limitations	90.2 (22.9)	100.0 (0.0)	97.8 (8.6)	85.5 (26.3)	97.5 (8.9)	89.4 (23.9)
- Energy/fatigue	62.4 (21.3)	65.6 (14.5)	67.7 (22.4)	66.5 (16.9)	73.5 (12.7)	69.6 (13.3)
- Emotional well-being	76.5 (14.6)	76.9 (12.0)	82.4 (10.1)	75.7 (14.3)	85.9 (8.7)	80.4 (11.5)
- Social functioning	92.7 (11.7)	84.7 (27.1)	92.5 (11.4)	92.4 (15.0)	96.3 (8.4)	94.9 (10.7)
- Pain	82.9 (9.9)	74.4 (20.3)	82.3 (18.5)	84.7 (14.7)	87.7 (13.1)	79.4 (18.0)
- General health	77.4 (19.5)	75.6 (17.9)	76.3 (21.2)	75.7 (15.0)	85.0 (15.3)	76.1 (18.3)
- Physical health score	87.1 (9.5)	85.1 (9.9)	83.8 (18.0)	87.4 (12.0)	90.9 (7.8)	85.5 (14.1)
- Mental health score	80.4 (12.1)	81.8 (8.4)	85.1 (10.5)	80.0 (14.0)	88.3 (6.9)	83.6 (11.9)
- Aggregate score	83.7 (10.0)	83.5 (7.3)	84.4 (13.5)	83.7 (10.9)	89.6 (6.3)	84.5 (11.3)
WOMAC						
- Total score (0-96)	28.6 (5.5)	28.7 (6.3)	31.9 (12.6)	29.0 (6.7)	28.2 (8.3)	30.4 (8.1)
- Pain score (0-20)	6.4 (1.8)	6.4 (2.8)	6.7 (2.4)	6.5 (2.2)	6.2 (2.3)	6.1 (1.6)
- Stiffness score (0-8)	3.4 (1.3)	3.2 (1.1)	3.5 (1.6)	2.8 (1.1)	2.7 (1.1)	3.5 (1.2)
- Physical function score (0-68)	18.8 (3.3)	19.0 (4.6)	21.7 (9.0)	19.7 (4.1)	19.3 (5.4)	20.8 (5.9)
Change baseline - 48 weeks						

SF-36						
- *Physical functioning*	+0.6 (4.8)	0.0 (6.0)	+0.4 (4.1)	-3.3 (15.3)	-1.6 (6.3)	-0.5 (9.7)
- *Physical role limitations*	+3.1 (15.5)	+3.1 (8.8)	+5.4 (35.6)	-7.1 (28.7)	-4.0 (22.5)	+0.0 (30.9)
- *Emotional role limitations*	+4.2 (16.7)	-4.2 (11.8)	+2.4 (8.9)	+4.8 (33.8)	0.0 (9.6)	+9.3 (25.1)
- *Energy/fatigue*	+10.0 (17.4)	+9.4 (12.9)	+2.9 (13.7)	+3.0 (12.7)	+2.6 (8.8)	+0.3 (9.0)
- *Emotional well-being*	+5.8 (14.2)	+5.0 (9.5)	+4.6 (9.1)	+5.2 (10.4)	+0.8 (5.8)	+3.3 (7.6)
- *Social functioning*	+3.9 (10.9)	+12.5 (24.1)	+1.8 (12.8)	+2.5 (15.5)	+1.0 (11.4)	+2.1 (8.8)
- *Pain*	+7.0 (11.9)	+14.7 (13.9)	+1.8 (9.1)	-1.2 (17.8)	-0.9 (8.0)	+1.5 (15.2)
- *General health*	+5.3 (12.3)	+5.6 (12.1)	+3.9 (10.2)	+5.8 (8.8)	+2.4 (9.4)	-1.7 (13.0)
- *Physical health score*	+4.0 (8.0)	+5.9 (5.7)	+2.9 (11.5)	-2.4 (17.9)	-1.0 (7.6)	-0.2 (13.7)
- *Mental health score*	+6.0 (11.4)	+5.7 (5.9)	+2.9 (7.7)	+4.8 (13.5)	+1.1 (5.3)	+3.7 (8.9)
- *Aggregate score*	+5.0 (8.9)	+5.8 (4.6)	+2.9 (7.8)	+2.9 (10.3)	+0.0 (5.6)	+1.8 (8.7)
WOMAC						
- *Total score (0-96)*	-2.3 (5.5)	-3.0 (6.2)	-1.1 (5.1)	-1.0 (4.7)	+2.0 (7.8)	-1.1 (6.6)
- *Pain score (0-20)*	-0.9 (1.8)	-0.8 (2.9)	+0.4 (2.7)	-0.4 (1.7)	+0.6 (2.4)	-0.3 (1.1)
- *Stiffness score (0-8)*	-0.7 (1.3)	-0.6 (1.2)	-0.5 (0.9)	-0.2 (1.1)	+0.2 (1.0)	-0.1 (1.2)
- *Physical function score (0-68)*	-0.6 (3.4)	-1.6 (5.2)	-1.0 (3.3)	-0.5 (2.7)	+1.2 (5.3)	-0.7 (5.6)

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).

Supplementary Table S1: Week 48 safety-related blood work assessment

	5 mg	10 mg	Placebo	F(df1, df2)	p-value
	N=38	N=33	N=34		
	Mean (SD) [*]	Mean (SD) [*]	Mean (SD) [*]		
Glucose (mg/dL)	91.3 (9.6)	91.8 (8.1)	89.7 (9.5)	F(2, 101) = 0.489	0.614
LDL cholesterol (mg/dL)	107.9 (34.8)	96.2 (34.1)	103.5 (30.7)	F(2, 102) = 1.095	0.339
Non-HDL cholesterol (mg/dL)	126.0 (37.6)	116.1 (38.4)	121.3 (32.5)	F(2, 101) = 0.647	0.526
Triglycerides (mg/dL)	87.1 (33.2)	95.3 (52.1)	84.3 (36.0)	F(2, 102) = 0.659	0.520
HbA1c (%)	5.2 (0.3)	5.3 (0.3)	5.3 (0.3)	F(2, 102) = 0.961	0.386
Insulin (uIU/mL)	6.0 (4.7)	7.2 (4.2)	5.5 (3.2)	F(2, 100) = 1.566	0.214
ALT (U/L)	20.1 (10.4)	25.0 (10.3)	22.0 (10.7)	F(2, 102) = 1.967	0.145
AST (U/L)	21.7 (6.4)	24.6 (7.4)	23.0 (8.5)	F(2, 102) = 1.355	0.263
BUN (mg/dL)	17.1 (3.6)	17.2 (3.9)	16.6 (3.9)	F(2, 102) = 0.277	0.759
Creatinine (mg/dL)	0.9 (0.2)	0.9 (0.2)	1.0 (0.3)	F(2, 102) = 0.597	0.553
eGFR (mL/min/1.73m^2)	86.3 (13.6)	84.6 (12.3)	81.5 (15.6)	F(2, 98) = 1.026	0.362

ALT: alanine aminotransferase; AST: aspartate aminotransferase; BMI: body mass index; BUN: blood urea nitrogen; eGFR: estimated glomerular filtration rate; HbA1c: hemoglobin A1c; HDL: high-density lipoprotein; LDL: low-density lipoprotein; SD: standard deviation.
Groups were compared using Analysis of Variance. [*]*p < 0.05*

Supplementary Table S2: Baseline Dexa outcomes and absolute change after 48 weeks

Dexa Variable	Baseline				
	5 mg	**10 mg**	**Placebo**	**F(df1, df2)**	**p-value**
Visceral adipose tissue mass (g)	972.4 (900.2)	1016.2 (800.4)	866.5 (635.9)	F(2, 110) = 0.356	0.701
Bone mineral content (g)	2680.4 (598.6)	2901.6 (493.4)	2830.4 (676.6)	F(2, 104) = 1.239	0.294
Lean tissue mass (g)	50018.5 (11058.6)	54715.6 (10518.4)	51886.5 (12339.9)	F(2, 109) = 1.561	0.215
Bone Mineral Density (g/cm2)	1.1996 (0.1662)	1.2765 (0.1422)	1.2488 (0.1644)	F(2,106) = 2.054	0.133
Dexa Variable	Change baseline - 48 weeks				
	5 mg	**10 mg**	**Placebo**	**F(df1, df2)**	**p-value**
Visceral adipose tissue mass (g)	-39.9 (185.2)	+13.1 (246.2)	+35.3 (290.8)	F(2, 101.408) = 0.978	0.379
Bone mineral content (g)	-31.9 (8.22)	+19.4 (104.3)	-8.7 (93.6)	F(2,104.415) = 1.403	0.250
Lean tissue mass (g)	-66.0 (2456.0)	+517.8 (2440.2)	-444.6 (1838.9)	F(2,126.996) = 1.115	0.331
Bone Mineral Density (g/cm2)	0.1593 (0.0097)	0.0008 0.0352)	-0.0015 (00289)	F(2,166.294) = 1.596	0.552

Groups were compared using Analysis of Variance (baseline) and linear mixed effects model (change from week 0 through 48). Values provided as mean (standard deviation).

Supplementary Table S3: Baseline SF-36 and WOMAC and absolute change at 48 weeks

	Baseline				48 weeks			
	5 mg	**10 mg**	**Placebo**	**p-value**	**5 mg**	**10 mg**	**Placebo**	**p-value**
SF-36								
- Physical functioning	94.9 (7.4)	95.7 (8.7)	94.5 (9.5)	0.821	-1.6 (12.0)	-1.2 (6.1)	-0.2 (7.7)	0.754
- Physical role limitations	93.8 (18.6)	95.1 (11.7)	87.8 (27.4)	0.263	-2.7 (24.1)	-2.3 (20.1)	+2.3 (32.6)	0.970
- Emotional role limitations	87.5 (24.7)	98.2 (7.7)	92.8 (19.5)	0.054	+4.5 (27.4)	-1.0 (10.2)	+6.3 (19.7)	0.401
- Energy/fatigue	64.8 (18.7)	71.5 (13.4)	68.8 (17.3)	0.209	+6.1 (15.2)	+4.2 (10.2)	+1.4 (11.2)	0.081
- Emotional well-being	76.0 (14.2)	83.7 (10.2)	81.2 (10.9)	**0.019**	+5.4 (12.0)	+1.8 (6.9)	+3.9 (8.2)	0.479
- Social functioning	92.5 (13.5)	93.4 (15.7)	93.9 (10.9)	0.896	+3.1 (13.5)	+3.8 (15.8)	+1.9 (10.6)	0.745
- Pain	83.9 (12.8)	84.4 (16.0)	80.6 (18.0)	0.528	+2.4 (15.9)	+2.9 (11.7)	+1.6 (12.7)	0.682
- General health	76.4 (16.8)	82.6 (16.2)	76.2 (19.2)	0.203	+5.6 (10.3)	+3.2 (10.0)	+0.8 (12.0)	**0.014**
- Physical health score	87.2 (10.9)	89.5 (8.6)	84.7 (15.5)	0.254	+0.4 (14.6)	+0.6 (7.7)	+1.2 (12.7)	0.850
- Mental health score	80.2 (13.1)	86.7 (7.7)	84.2 (11.3)	**0.037**	+5.3 (12.5)	+2.2 (5.7)	+3.4 (8.3)	0.385
- Aggregate score	83.7 (10.4)	88.1 (7.0)	84.5 (12.0)	0.142	+3.8 (9.6)	+1.4 (5.9)	+2.3 (8.2)	0.335
WOMAC								
- Total score (0-96)	28.8 (6.2)	28.3 (7.8)	31.0 (10.0)	0.325	-1.6 (5.0)	+0.8 (7.7)	-1.1 (5.9)	0.325
- Pain score (0-20)	6.5 (2.0)	6.3 (2.4)	6.4 (2.0)	0.900	-0.6 (1.8)	+0.3 (2.5)	0.0 (1.9)	0.184
- Stiffness score (0-8)	3.1 (1.2)	2.9 (1.1)	3.5 (1.4)	0.101	-0.4 (1.2)	0.0 (1.1)	-0.3 (1.1)	0.456

- Physical function score (0-68)	19.3 (3.7)	19.2 (5.1)	21.2 (7.2)	0.220	-0.6 (3.0)	+0.5 (5.3)	-0.8 (4.6)	0.614

SF-36: short form 36; WOMAC: Western Ontario and McMaster Universities Osteoarthritis Index. Values provided as mean (standard deviation).

Figure 1

Figure 2

Figure 3

Figure 4

Supplementary Figure S1

a

b

Supplementary Figure S2

a

b

Supplementary Figure S3

Supplementary Figure S4

Supplementary Figure S6